COVID-19: KEEPING UP WITH A MOVING TARGET
November 18, 2020 UPDATE

Paul Auwaerter, MD, MBA, FIDSA
Clinical Director, Division of Infectious Diseases
Sherrilyn and Ken Fisher Professor of Medicine
Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine

dkbmed

PIM Postgraduate Institute for Medicine

JOHNS HOPKINS NURSING

CME Information

Jointly provided by Postgraduate Institute for Medicine, DKBmed, and the Institute for Johns Hopkins Nursing.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Name of Faculty or Presenter	Reported Financial Relationship
Paul G. Auwaerter, MD, MBA, FIDSA	Scientific Advisor: DiaSorin, Shionogi Inc. JNJ: Ownership equity

Dr. Auwaerter has indicated that he will be referencing the unlabeled or unapproved use of agents currently being investigated in on-going studies and trials, including a monoclonal antibody cocktail, dexamethasone, and several vaccine platforms.

All activity, content, and materials have been developed solely by the activity directors, planning committee members, and faculty presenters, and are free of influence from a commercial entity.

CME Information

To attest for CME/CE/AAPA credit, please visit

COVID19.dkbmed.com

Learning Objectives

- Discuss the CDC recommendations for holiday gatherings
- Describe the current status of vaccine development

Thank You

This activity is supported by an educational grant from Pfizer, Inc. and in-kind support by DKBmed, LLC.

All activity content and materials have been developed solely by the activity directors, planning committee members, and faculty presenters.

Please see **COVID19.DKBmed.com** for additional resources and educational activities

Paul Auwaerter, MD, MBA, FIDSA
Clinical Director, Division of Infectious Diseases
Sherrilyn and Ken Fisher Professor of Medicine
Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine

Global COVID Cases (11/16/2020)



https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6

A very successful Virus--
Takes Advantage of Need for Human Bonding



https://coronavirus.jhu.edu/testing/individual-states

A Very Successful Virus--
Takes Advantage of Need for Human Bonding



https://coronavirus.jhu.edu/testing/tracker/map/percent-positive

COVID CASES/100,000 – 7d Average



JHU/Wash Post 11/16/20

dkbmed

COVID-19
KEEPING UP WITH A MOVING TARGET

Don’t Go -
If You Do, Look Into Details



November 16, 2020

Where Are Most Infections Acquired?



Lee et al, *Science* 23 Oct 2020: Vol. 370, Issue 6515, pp. 406-407

Youth Is Wasted on the Young (?) --George Bernard Shaw

FIGURE. Cumulative number of confirmed COVID-19 cases, by age group (N = 757) — Winnebago County, Wisconsin, March 1–July 18, 2020



Wilson, *MMWR Weekly* / October 16, 2020 / 69(41);1497–1502

Home for the Holidays - Grandparents Beware

- Voluntary testing
- Some but not all schools
- Will lower but not avoid all risk

Education

Before Thanksgiving, colleges plan to ramp up testing for coronavirus

A University of Wisconsin at Madison student exits an on-campus coronavirus testing site on Oct. 13. The school is among colleges that plan to expand testing before students leave campus for Thanksgiving. (Bing Guan/Reuters)

By Nick Anderson

November 2, 2020 at 10:00 a.m. EST

+ Add to list

Washington Post

CDC Recommendations: Holidays

- Limit numbers or keep to your bubble (keep local)
- If community rates increasing - more danger
  - Where are your guests coming from?
- Location: outside preferred
- Duration: short
- Mitigation: wear masks (even indoors), social distance (including when eating)
  - Loud talking, singing as increasing risks

https://www.cdc.gov/coronavirus/2019-ncov/daily-life-coping/holidays.html

Many Public Health Officials Say CDC Recommendations Too Lenient

- Canada—
  - Justin Trudeau canceling any in-person gatherings
- "Thanksgiving will be a Superspreader event"
  - Dr. William Schaffner, Professor of Vanderbilt University.
    - "In fact, I'm convinced, just looking at the way our general population is currently behaving."

No Go Recommendations

People who should not attend in-person holiday celebrations

People with or exposed to COVID-19

Do not host or participate in any in-person festivities if you or anyone in your household

- Has been diagnosed with COVID-19 and has not met the criteria for when it is safe to be around others
- Has symptoms of COVID-19
- Is waiting for COVID-19 viral test results
- May have been exposed to someone with COVID-19 in the last 14 days
- Is at increased risk of severe illness from COVID-19

People at increased risk for severe illness

If you are at increased risk of severe illness from COVID-19, or live or work with someone at increased risk of severe illness, you should

- Avoid in-person gatherings with people who do not live in your household.
- Avoid larger gatherings and consider attending activities that pose lower risk (as described throughout this page) if you decide to attend an in-person gathering with people who do not live in your household.

https://www.cdc.gov/coronavirus/2019-ncov/daily-life-coping/holidays.html

Considering Risk

Lower risk activities

- Having a small dinner with only people who live in your household
- Preparing traditional family recipes for family and neighbors, especially those at higher risk of severe illness from COVID-19, and delivering them in a way that doesn't involve contact with others
- Having a virtual dinner and sharing recipes with friends and family
- Shopping online rather than in person on the day after Thanksgiving or the next Monday
- Watching sports events, parades, and movies from home

Moderate risk activities

- Having a small outdoor dinner with family and friends who live in your community
  - Lower your risk by following CDC's recommendations on hosting gatherings or cook-outs.
- Visiting pumpkin patches or orchards where people use hand sanitizer before touching pumpkins or picking apples, wearing masks is encouraged or enforced, and people are able to maintain social distancing
- Attending a small outdoor sports events with safety precautions in place

Higher risk activities

Avoid these higher risk activities to help prevent the spread of the virus that causes COVID-19:

- Going shopping in crowded stores just before, on, or after Thanksgiving
- Participating or being a spectator at a crowded race
- Attending crowded parades
- Using alcohol or drugs, which can cloud judgement and increase risky behaviors
- Attending large indoor gatherings with people from outside of your household

https://www.cdc.gov/coronavirus/2019-ncov/daily-life-coping/holidays.html

Vaccines and monoclonal antibodies—Some good news

PREVENTION

The COVID-19 Vaccine Race

- 300 candidate vaccines
- 61 in human trials



All two injections except:
JNJ & CanSinoBio (single injections)

Vaccines in Phase 3 trials

- **Moderna (mRNA)**
- **BioNTech/Pfizer (mRNA)**
- CanSinoBio* (Ad5)
- Gamaleya* (Ad5/Ad26)
- Oxford/AstraZeneca (ChAdOx1)
- Sinovac* (inactivated)
- Wuhan Inst/Sinopharm (inactivated)
- Sinopharm* (inactivated)
- Murdoch (BCG vaccine)
- JNJ (Ad26)
- Bharat (inactivated)

* Approved for early use in some countries

NYT 11/16/2020

Bamlanivimab FDA EUA (11/10/20)



The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Peter Chen, M.D., Ajay Nirula, M.D., Ph.D., Barry Heller, M.D., Robert L. Gottlieb, M.D., Ph.D., Joseph Boscia, M.D., Jason Morris, M.D., Gregory Huhn, M.D., M.P.H.T.M., Jose Cardona, M.D., Bharat Mocherla, M.D., Valentina Stosor, M.D., Imad Shawa, M.D., Andrew C. Adams, Ph.D., Jacob Van Naarden, B.S., Kenneth L. Custer, Ph.D., Lei Shen, Ph.D., Michael Durante, M.S., Gerard Oakley, M.D., Andrew E. Schade, M.D., Ph.D., Janelle Sabo, Pharm.D., Dipak R. Patel, M.D., Ph.D., Paul Klekotka, M.D., Ph.D., and Daniel M. Skovronsky, M.D., Ph.D., for the BLAZE-1 Investigators*

- BLAZE-1 RCT, interim analysis
- Mild/moderate COVID-19
- Single dose, 456 non-hospitalized patients

- 1° endpoint, change viral load d11 NOT met

- Approval based on 2° endpoint:
- Hospitalization or ED visit at d28
- 3% vs. 10% placebo
- --Unclear how many ED vs. hospital

Role: (+) SARS-CoV-2, age ≥ 12, high risk for severe COVID-19

NEJM October 28, 2020

To receive CME/CE/AAPA credit:

- Complete the evaluation on at COVID19.DKBmed.com
- Upon registering and successfully completing the activity evaluation, you will have immediate access to your certificate.

To access more resources related to COVID-19:

- Access our resource hub at COVID19.DKBmed.com

To ask your own question, email: QA@dkbmed.com